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INTRODUCTION
Acetaminophen (APAP) is one of the most widely used 
analgesics and antipyretics, and it is considered safe to use 
within the maximum daily dose of 3,250 mg and the maximum 
single dose of 650 mg (Krenzelok, 2009). However, its over-
use or co-existing risk factors that can exacerbate liver func-
tion such as narcotic, alcohol drinking or polypharmacy, often 
cause drug-induced liver injury (DILI) (Watson et al., 2004; 
Larson et al., 2005). DILI, namely hepatotoxicity induced by 
drugs is one of the most frequent and severest forms of ad-
verse drug reaction (Lazarou et al., 1998). The incidence of 
DILI is low varying from 1/100,000 to 1/10,000 but, its impact 
is huge since acute liver failure with high mortality can occur 
(Chang and Schiano, 2007; Stephens et al., 2012). More than 
1,000 drugs were known to cause DILI in human (Lewis, 2000; 
Reuben et al., 2010). Of these APAP-induced DILI accounts 
for 46% of cases of fulminant liver failure in the United States 
(Ostapowicz et al., 2002). More than 200 million persons take 
APAP annually and among them about 200 persons die of ful-
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Drug-induced liver injury (DILI) is the serious and fatal drug-associated adverse effect, but its incidence is very low and individual 
variation in severity is substantial. Acetaminophen (APAP)-induced liver injury accounts for >50% of reported DILI cases but little 
is known for the cause of individual variations in the severity. Intrinsic genetic variation is considered a key element but the identity 
of the genes was not well-established. Here, pre-biopsy method and microarray technique was applied to uncover the key genes 
for APAP-induced liver injury in mice, and a cause and effect experiment employing quantitative real-time PCR was conducted to 
confirm the correlation between the uncovered genes and APAP-induced hepatotoxicity. We identified the innately and differen-
tially expressed genes of mice susceptible to APAP-induced hepatotoxicity in the pre-biopsied liver tissue before APAP treatment 
through microarray analysis of the global gene expression profiles (Affymetrix GeneChip® Mouse Gene 1.0 ST for 28,853 genes). 
Expression of 16 genes including Gdap10, Lpl, Gabra3 and Ccrn4l were significantly different (t-test: FDR <10%) more than 1.5 
fold in the susceptible animals than resistant. To confirm the association with the susceptibility to APAP-induced hepatotoxicity, 
another set of animals were measured for the expression level of selected 4 genes (higher two and lower two genes) in the liver 
pre-biopsy and their sensitivity to APAP-induced hepatotoxicity was evaluated by post hoc. Notably, the expressions of Gabra3 
and Lpl were significantly correlated with the severity of liver injury (p<0.05) demonstrating that these genes may be linked to the 
susceptibility to APAP-induced hepatotoxicity.
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minant hepatic failure from over-dosage (Park, 2006). 
APAP induces hepatotoxicity via the generation of reactive 
and electrophilic metabolites like N-acetyl-p-benzoquinone 
imine (NAPQI) by cytochrome P450 that can result in glutathi-
one (GSH)-adduct formation, covalent binding to vital endog-
enous macromolecules, and depletion of cellular antioxidant 
reserve (Bessems and Vermeulen, 2001). N-acetylcysteine 
given (NAC) within 12 h seems to be effective in protecting 
most patients against severe liver damage induced by APAP 
(Prescott et al., 1977) but frequently APAP-induced DILI could 
be recognized only after symptoms have developed by when 
NAC is no longer effective, reflecting that APAP-induced hep-
atotoxicity progresses in multiple stages and diverse factors 
may be involved that include inflammation, metabolism and 
lipid synthesis (Hinson et al., 2010). Moreover, APAP-induced 
DILI appears with variable degrees of severity ranging from 
minimal increases in the levels of serum alanine transaminase 
(ALT)/aspartate transaminase (AST) to severe hepatic necro-
sis and fatal hepatic failure (Larson et al., 2005; Watkins et al., 
2006; Yun et al., 2014), reflecting the existence of “individual 
factors” in the manifestation of APAP-induced hepatotoxicity.
To identify factors that determine the severity of APAP-
induced hepatotoxicity or to develop a biomarker to screen 
susceptible individuals, various approaches have been at-
tempted. Liu et al. (2010) have analyzed hepatic gene expres-
sions related to APAP toxicity using resistant strain SJL/J and 
three sensitive strains C57BL/6J, DBA/2J, and SM/J. Stamper 
et al. (2010) have found several genes with significant differ-
ences in the expression between non-toxic APAP regio-isomer 
3-hydroxyacetanilide and APAP in TGF-α transgenic mouse 
hepatocytes. Also, Umbright et al. (2010) have reported that 
many blood genes associated with inflammation, immune, 
stress responses and energy metabolism were statistically 
different in their expression levels following APAP treatment. 
While these approaches are effective in the identification 
of target molecules or markers that can diagnose the extent 
of APAP-induced hepatotoxicity, their applicability as biomark-
ers to screen-out susceptible individuals is limited since the 
exposure to APAP might have extensively altered the genetic 
landscape due to direct or collateral tissue damages and sub-
sequent inflammatory responses. Recently, to draw an intact 
genetic picture without the interference from APAP-induced 
toxicity, we examined through the comparison of pre-dose 
blood genes and the severity of APAP-induced hepatotoxic-
ity posterior in rats in vivo, which demonstrated that protein 
kinase A (PKA) inhibitor alpha (Pkia) expression level in pre-
dose blood can be employed to predict susceptible individuals 
without the interference from the exposure to APAP (Yun et 
al., 2014). More importantly, this study has provided an insight 
into the role of PKA in the manifestation of APAP-induced hep-
atotoxicity. This approach has been further corroborated by 
Lu et al. (2015) who demonstrated that four genes, including 
Incenp, Rpgrip1, Sbf1, and Mmp12, which are associated with 
cell proliferation and tissue repair functions, in the blood col-
lected from individuals prior and posterior to APAP administra-
tion can be used for identifying susceptible population to DILI. 
However, these studies offered surrogate genetic biomarkers 
in blood rather than that of direct target, liver, therefore, its 
utility and implication might be limited. In this study, we further 
investigated the transcriptome in the biopsy of liver pre-dose 
to uncover the genetic factors for individual susceptibility of 
APAP-induced hepatotoxicity in mice in vivo in an effort to 
provide a clue to understand the progression of, and defense 
mechanisms against APAP-induced DILI. 
MATERIALS AND METHODS
Animals
Outbred ICR mice was selected as the experimental spe-
cies for this study since rats do not manifest a clear profile of 
blood chemistry to APAP-induced hepatotoxicity when com-
pared with the responses to carbon tetrachloride or D-galac-
tosamine (Shin et al., 2014). Male ICR mice aged 7 weeks 
were purchased from Jung-Ang Lab Animals (Seoul, Korea) 
and housed in a specific pathogen-free (SPF) facility of Ewha 
Womans University. We used ICR mice, one of the outbred 
strains, which retain a certain level of genetic diversity in the 
test population in present study. The mice were kept under 
controlled environmental conditions (23 ± 3°C, 40-60% rela-
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Fig. 1. Experimental scheme for pre-biopsy. To identify the innate genes for individual variation of liver injury, we analyzed the gene expres-
sion profiles in the liver pre-biopsied from individual mice prior to APAP administration and compared them with the individual severity of 
liver injury after APAP administration. ALT: alanine aminotransferase, T.bilirubin: Total Bilirubin, Sus: susceptible, Res: resistant.
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tive humidity, 12/12 h dark-light cycle) with ad libitum access 
to laboratory normal diets (Purina Co., Seoul, Korea) and tab 
water. All protocol involving animals were carried out in accor-
dance with the guidelines of the Institutional Animal Care and 
Use Committee of Ewha Womans University.
Experimental protocol
To identify the innate genes for individual variation of liver 
injury, we analyzed the gene expression profiles in the liver 
pre-biopsied from individual mice prior to the oral adminis-
tration of APAP (Sigma, St. Louis, MO, USA) and compared 
them with the individual severity of liver injury after APAP 
administration according to the method described previously 
(Yun et al., 2009, 2010) (Fig. 1). In brief, the mice were ran-
domly assigned into three groups consisting of negative 
control group (no biopsy group) (N=5), biopsy control group 
(N=5), and APAP group (N=32). The operation was performed 
for minimum liver biopsies (about 10 mg) from left lobe of the 
liver of anesthetized mice in biopsy groups (biopsy control 
group and APAP group) using an isoflurane vaporizer (Mid-
mark, Orchard Park, OH, USA) with an isoflurane of 1.5% to 
3% and an oxygen flow of 0.5 L/min. After conducting the su-
tures to close the subcutis tissue and the skin using Surgifit 
6-0 (AILEE, Busan, Korea) and Black silk 6-0 (AILEE). For 
the assessment of postoperative recovery, ALT, AST, albumin, 
albumin/globulin ratio (A/G ratio), total bilirubin and bile acid 
were measured using serum samples from blood collected via 
retro-orbital plexus of anesthetized animals into a gel serum 
separator plain blood tubes (MiniCollect 0.8 ml Z Serum Sep, 
Greiner Bio-One, Frickenhausen, Germany). After recovery for 
3 weeks, the mice were administered with APAP through oral 
gavage at a dose of 300 mg/kg (dissolved in deionized water) 
according to a previous method (Saha and Nandi, 2009) with 
minor modifications. At 24 h after administrations of APAP, we 
performed the biochemical analysis using the blood collected 
via the postcaval vein from anesthetized animals, and then 
conducted microarray analysis using the pre-collected liver 
samples of the 10 animals (5 susceptible and 5 resistant) se-
lected based on the results of the biochemical analysis and 
compared the gene expressions with the individual severity 
of liver injury after APAP administration to identify the innate 
genes for individual variation of liver injury. Additionally, to 
identify whether the innate genes selected by microarray ex-
periment can predict the susceptibility of liver injury, we con-
ducted the real-time PCR analysis for selected genes using 
liver samples biopsied from another set of animals (N=32) and 
then compared the gene expression with individual severity of 
liver injury after APAP administration (300 mg/kg, p.o.). The 
severity of liver injury were analyzed with the biochemical in-
dicators, including ALT, total bilirubin, AST, lactate dehydroge-
nase (LDH) and bile acid at 24 h after administrations of APAP.
RNA isolation and microarray analysis
The liver tissue biopsied before APAP administration was 
processed with TRIzol reagent (Invitrogen, Carlsbad, CA, 
USA) for isolation of total RNA. RNA precipitates were dis-
solved in RNase free DEPC treated water (USB, Cleveland, 
OH, USA). The concentration of RNA was determined Nano 
drop 1000 spectrophotometer (NanoDrop Technologies, Inc., 
Wilmington, DE, USA). Affymetrix (Santa Clara, CA, USA) 
GeneChip1 Mouse Gene 1.0 ST arrays were used to analyze 
the differential gene expressions, as described previously 
(Yun et al., 2009). The normalized scanned probe array data 
were compared between the groups to generate p-value and 
signal log ratio (fold change). Unpaired t-test was applied to 
determine statistically reliable probe sets.
Reverse transcription-polymerase chain reaction (RT-PCR)
Relative expression levels of mRNAs were measured by 
quantitative real-time PCR. Total RNA, extracted from liver 
prior to APAP treatment, was used to synthesize cDNA using 
pre-master mix with oligo dT (Bioepis, Seoul, Korea). Each re-
action was performed using power SYBR Green PCR master 
mix in a 7300 real-time PCR machine (Applied Biosystems, 
Warrington, UK). The sequence of primers of mice liver were 
as follows: forward Gdap10, 5′-GCC TGG CAC GTA GAA CAA 
AC-3′; reverse Gdap10, 5′-ACT AGT TTG CTG CCC TCG TT-
3′; forward Lpl, 5′-TCA GAG CCA AGA GAA GCA GC-3′; re-
verse Lpl, 5′-ATC TCG AAG GCC TGG TTG TG-3′; forward 
Klf10, 5′-AGC AAG GGT CAC TCC TCA GA-3′; reverse Klf10, 
5′-AGG TTT TTC CCC TGT GTG TG-3′; forward Malat1, 5′-
GAC AAA AGG CTA AAG TGG ATG-3′; reverse Malat1, 5′-TTG 
TGC TGG CTC TAC CAT T-3′; forward Ccrn4l, 5′-CCT GGA 
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Fig. 2. Effects of the liver biopsy on serum biochemistry after re-
covery for 3 weeks. Levels of ALT, AST, albumin, A/G ratio, total 
bilirubin and bile acid in the serum of mice recovered from or not 
undergone pre-biopsy. The data are presented as means ± SE. 
NC, Negative control group; Biopsy, Biopsy control group.
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GTG CAA GGA GTC TG-3′; reverse Ccrn4l, 5′-CTG GGT GAT 
GTT CTG CAG GT-3′; forward Gabra3, 5′-CCA ACA GCG ATT 
GCT TCA CC-3′; reverse Gabra3, 5′-GGC AAA GAG CAC 
AGG GAA GA-3′; forward GAPDH, 5′-CTA CCC CCA ATG 
TGT CCG TC-3′; reverse GAPDH, 5′-AAG TCG CAG GAG 
ACA ACC TG-3′. Annealing temperature were 51°C. For real-
time PCR data, fold change results were calculated using 2-ΔΔCt 
relative to the internal reference gene (GAPDH) and the mean 
of all samples. The change in the Ct (ΔCt) of the target genes 
was calculated as ΔCt=(Ct of target genes)-(Ct of GAPDH). 
The ratio of the target gene to the housekeeping gene was 
calculated and expressed as 2-ΔCt. Τhis ratio was then used to 
evaluate the expression level of the target gene within each 
animal. To determine the fold changes in gene expression 
among animals, the normalized gene expression of the target 
genes was divided by the normalized expression of the same 
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Fig. 4. Biochemical and histological analysis between groups after APAP treatment. The mice were orally administrated with APAP at a 
dose of 300 mg/kg. At 24 h after APAP administration, histological examination (A) and blood biochemistry for lactate dehydrogenase (LDH, 
U/L), aspartate aminotransferase (AST, U/L)) and bile acid (μmol/L) (B) were conducted. Representative H&E stained liver tissue (bar = 200 
μm). The data are presented as means ± SE. *Significantly different from Con group (p<0.05). Con, Negative control group; Res, resistant 
group; Sus, susceptible group.
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Fig. 3. Selection of the groups based on the serum ALT and total bilirubin after APAP administration. (A) Selection of the samples for mi-
croarray analysis (N=5/group). (B) ALT and total bilirubin levels of selected groups. The data are presented as means ± SE (*p<0.05 and 
**p<0.01). Con, Negative control group; Res, resistant group; Sus, susceptible group.
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target gene in the sample with the lowest level of the normal-
ized gene expression of the target genes, expressed as 2-ΔΔCt. 
Statistical analysis
All data were analyzed by student t-test or one-way analy-
sis of variance (ANOVA) followed by post hoc Tukey’s multiple 
range tests to determine treatment effect and to compare dif-
ferences between group means. Differences were considered 
to be significant at p<0.05.
RESULTS
Assessment of the influences of liver biopsy on liver  
function of ICR mice 
Pre-biopsy scheme needs the liver biopsy at the naïve 
condition prior to APAP administration to identify the innate 
genetic factors associated with the individual variation of 
APAP-induced liver injury afterwards (Fig. 1). Firstly, to check 
if pre-biopsy procedure does not affect normal liver function of 
mice, small amount of liver tissue (about 10 mg) was pre-biop-
sied from the identical region of left lobe and liver function was 
evaluated after sufficient postoperative recovery (3 weeks) by 
measuring ALT, AST, albumin, A/G ratio, total bilirubin, and bile 
acid in the serum. As a result, liver function of biopsy con-
trol group was not statistically different from those in Negative 
control group (Fig. 2), suggesting that the effects of pre-biopsy 
scheme on the liver function are minimal for mice as shown in 
rats previously (Yun et al., 2010). 
Hepatotoxicity induced by APAP administration after liver 
biopsy
After liver pre-biopsy and postoperative recovery for 3 
weeks, APAP was orally administered to the ICR mice (N= 
32), an outbred strain at a dose of 300 mg/kg. The APAP-treat-
ed mice exhibited clear signs of liver injury, as indicated by 
increased serum ALT and total bilirubin (Fig. 3). Importantly, 
there was a substantial inter-animal variation in the level of 
these biochemical indicators, suggesting that mice can dis-
play different susceptibility to APAP. On the basis of ALT and 
total bilirubin levels, animals could be grouped into 2 groups, 
that is, susceptible and resistant animals (top 5, susceptible 
and bottom 5, resistant, Fig. 3A). Serum ALT and total biliru-
bin in susceptible group were substantially higher when com-
pared with both Negative control group and resistant group 
(Fig. 3B, 3C). Further histological examination (Fig. 4A) and 
blood biochemistry (Fig. 4B) also revealed that the animals 
grouped as susceptible manifested higher toxic response to 
APAP than resistant which could be readily determined by sig-
nificantly higher liver toxicity markers and massive hepatic in-
jury including numerous apoptotic cells and inflammatory cell 
infiltration in the liver tissue.
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Gene expression analysis with microarray to identify 
genes associated with susceptibility to APAP-induced 
hepatotoxicity
To determine the genetic factors associated with these 
inter-individual variations to APAP-induced hepatotoxicity, mi-
croarray analysis was performed with the liver samples of 5 
susceptible and 5 resistant animals pre-obtained before APAP 
treatment as described in scheme (Fig. 1). The reliability of 
the transformed and normalized data was statistically ana-
lyzed using one-way ANOVA. This was visualized by hierar-
chical clustering of the calculated data from the experiment 
(Fig. 5A). From this analysis, 16 genes (excluding unknown 
sequences and noncoding genes) were found to be different 
with statistical reliability at p<0.05 with more than 1.5 fold dif-
ference between two groups in their expression levels (Table 
1). Among them, uppermost two genes expressed higher in-
nately in susceptible group were found to be Gdap10 and Lpl, 
and lowermost two genes expressed lower innately in suscep-
tible group were Gabra3 and Ccrn4l (Fig. 5B, 5C).
Prediction of the susceptibility of animals to APAP-
induced liver injury by real-time PCR analysis of the 
selected genes
To further confirm whether the individual expression levels 
of Gdap10, Lpl, Ccrn4l and Gabra3 are related to the inter-
individual variation in the susceptibility of APAP-induced liver 
injury indeed, the expression of these genes was analyzed 
with liver biopsy samples pre-collected from 32 animals before 
APAP-treatment using quantitative real-time PCR analysis. 
While a meaningful relationship could not be found with the 
expression levels of Gdap10 and Ccrn4l with the severity of 
APAP-induced hepatotoxicity, the innate expression level of 
Gabra3 matched well with the severity of APAP-induced liver 
injury as could be determined by the strong correlation with 
APAP-induced AST (Spearman Correlation Analysis, p<0.05; 
Correlation coefficients, -0.4209) (Fig. 6A) and ALT (Spear-
man Correlation Analysis, p<0.05; Correlation coefficient, 
-0.4012) decrease (Fig. 6B). Moreover, the innate expression 
level of Lpl matched well with the severity of APAP-induced 
liver injury as could be determined by the strong correlation 
with APAP-induced total bilirubin (Spearman Correlation Anal-
ysis, p<0.05; Correlation coefficient, 0.4052) increases (Fig. 
6C), of which relationships were further corroborated by the 
comparison of AST, ALT and total bilirubin of grouping based 
on the genes (Fig. 6D-6F). 
 
DISCUSSION
Here, we explored the genetic markers in the liver that are 
associated with the individual susceptibility to APAP-induced 
hepatotoxicity in ICR mice employing pre-biopsy scheme. 
Through this approach, we could identify that low Gabra3 
and high Lpl expression may be related to the susceptibility 
to APAP-induced hepatotoxicity. More importantly, we could 
confirm that susceptible animals could roughly be predicted 
through determining the expression levels of Gabra3 and Lpl 
in liver. In addition, this study suggests that Gabra3 may play 
a protective role against APAP-induced hepatotoxicity in the 
liver while Lpl may contribute to the development or aggrava-
tion of liver damages, which warrant further studies.
In the present study, a substantial inter-individual variation Ta
bl
e 
1.
 C
on
tin
ue
d
G
en
e
N
C
B
I 
R
ef
S
eq
 N
o.
D
es
cr
ip
tio
n
lo
g2
 
ra
tio
A
bs
ol
ut
e 
fo
ld
 c
ha
ng
e
p-
va
lu
e
G
O
 P
ro
ce
ss
P
di
lt
N
M
_0
27
94
3
P
ro
te
in
 d
is
ul
fid
e 
is
om
er
as
e-
lik
e,
  
te
st
is
 e
xp
re
ss
ed
0.
60
1.
51
0.
00
44
M
ul
tic
el
lu
la
r o
rg
an
is
m
al
 d
ev
el
op
m
en
t /
/ s
pe
rm
at
og
en
es
is
 //
 b
io
lo
gi
ca
l_
pr
oc
es
s 
//  
m
et
ab
ol
ic
 p
ro
ce
ss
 //
 c
el
l d
iff
er
en
tia
tio
n 
// 
ce
ll 
re
do
x 
ho
m
eo
st
as
is
 //
  
ce
llu
la
r_
co
m
po
ne
nt
 //
 e
nd
op
la
sm
ic
 re
tic
ul
um
 m
ol
ec
ul
ar
_f
un
ct
io
n 
// 
 
is
om
er
as
e 
ac
tiv
ity
M
ei
g1
N
M
_0
08
57
9
M
ei
os
is
 e
xp
re
ss
ed
 g
en
e 
1
0.
60
1.
51
0.
00
66
M
ei
os
is
 n
uc
le
us
 p
ro
te
in
 b
in
di
ng
C
cr
n4
l
N
M
_0
09
83
4
C
C
R
4 
ca
rb
on
 c
at
ab
ol
ite
 re
pr
es
si
on
 
4-
lik
e 
(S
. c
er
ev
is
ia
e)
-0
.6
3
1.
55
0.
00
08
R
hy
th
m
ic
 p
ro
ce
ss
G
ab
ra
3
N
M
_0
08
06
7
G
am
m
a-
am
in
ob
ut
yr
ic
 a
ci
d 
(S
ae
ed
 
et
 a
l.)
 A
 re
ce
pt
or
, s
ub
un
it 
al
ph
a 
3
-1
.5
6
2.
94
0.
00
34
Tr
an
sp
or
t /
/ i
on
 tr
an
sp
or
t /
/ c
hl
or
id
e 
tra
ns
po
rt 
// 
si
gn
al
 tr
an
sd
uc
tio
n 
// 
si
gn
al
 
tra
ns
du
ct
io
n 
// 
ga
m
m
a-
am
in
ob
ut
yr
ic
 a
ci
d 
si
gn
al
in
g 
pa
th
w
ay
 //
 s
yn
ap
tic
  
tra
ns
m
is
si
on
 //
 io
n 
tra
ns
m
em
br
an
e 
tra
ns
po
rt
Biomol  Ther 25(2), 112-121 (2017) 
www.biomolther.org
Kim et al.   Biomarkers for Susceptibility to APAP-Induced Hepatotoxicity
119
on APAP-induced hepatotoxicity was found among individual 
mouse, a well-known species susceptible to APAP, as evi-
denced by the histopathological examination and biochemis-
try analysis. Many previous transcriptomic approaches have 
examined the genetic landscape after APAP treatment and 
hence, can have limited applicability for the prediction of the 
individual susceptibility to APAP-induced hepatotoxicity. We 
previously demonstrated (Yun et al., 2009, 2010) that the pre-
dose scheme using pre-biopsied liver, which has a unique 
ability to fully regenerate after injury for the maintenance of 
its functions on metabolism and detoxification (Fausto et al., 
2006; Michalopoulos, 2007) may provide a useful tool for pre-
screening of the susceptible individual and for the discovery 
of key molecules in the manifestation of toxicity. In the current 
microarray experiment using the pre-biopsy method, we iden-
tified 16 genes including Gdap10, Klf10, Malat1, and Ccrn41 
(unpaired t-test: FDR <10% and fold change >1.5) as candi-
date genes predictive of severity on APAP-induced liver injury. 
Malat1, which has been known to be associated with a prog-
nostic marker for metastasis in early stages of lung adenocar-
cinoma (Ji et al., 2003; Gutschner et al., 2013) and ganglio-
side-induced differentiation-associated-protein 10 (Gdap10), 
 which is one of Gdap genes involved in different signal trans-
duction pathway (Liu et al., 1999). Klf10 has been known to 
regulate TGF-β signaling by blocking expression of the nega-
tive regulator, Smad7 (Johnsen et al., 2002), and activating 
expression of the positive effector, Smad2 (Johnsen et al., 
2002). Ccrn4l is a gene that encodes a circadian deadenyl-
ase, and its disruption in mice showed lower body weight and 
reduced visceral fat, reflecting resistance to fatty liver and di-
et-induced obesity (Green et al., 2007). Genes encoding cel-
lular components like Ankrd55, Cspp1, Dennd4a, Chd7, Snor-
d58b, Taf1d and Pdilt, are also shown to be associated. Other 
genes, Gas5, Dclre1c, and Meig1 also need further studies 
to examine their roles in the manifestation of APAP-induced 
hepatotoxicity.
Although DNA microarray can simultaneously quantitate 
the expression of thousands of genes, a second methodology 
including quantitative real-time RT-PCR is required to assess 
the accuracy of the candidate genes discovered by microar-
ray measurements (Draghici et al., 2006). Furthermore, the 
margin of difference in the expression is largely small, which 
necessitates a verification step. To confirm if the gene expres-
sion profiles detected with the microarray is reproducible and 
can be used to predict the animal to be susceptible or resistant 
to APAP-induced hepatotoxicity indeed, the liver samples pre-
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biopsied from another set of animals were undergone real-
time PCR analysis for the expression levels of 4 genes includ-
ing higher two and lower two genes selected from microarray 
analysis. 
Among four candidate genes, it is notable that the innate 
expression of Lpl in the liver was significantly correlated well 
with total bilirubin which was well-correlated with the severity 
of APAP-induced hepatotoxicity (Spearman correlation coef-
ficients 0.4052, p<0.05). The expression of Lpl in liver was ex-
pressed higher innately in susceptible group to APAP-induced 
hepatotoxicity when compared to resistant group. Lpl, which 
is a member of the lipase superfamily that includes pancre-
atic, hepatic and endothelial lipase, is widely expressed in 
many tissues such as liver, brain, heart and adipose tissues 
(Wang and Eckel, 2009). Kim et al. (2001) have demonstrated 
that the overexpression of Lpl, which has been known to be 
the rate-limiting enzyme involved with triglyceride hydrolysis 
(Goldberg, 1996), causes profound insulin resistance in liver 
(Baron et al., 1988). Insulin resistance can lead to selective 
accumulation of fatty acid-derived metabolites (i.e., fatty acyl 
CoA, ceramide, diacylglycerol) in liver and may be implicated 
in the development of acute liver failure (ALF) (Clark et al., 
2001) through impaired peripheral glucose utilization and a 
failure to fully suppress endogenous glucose production, 
contributing to the catabolic state that occurs in ALF. These 
suggest potential involvement of Lpl in the susceptibility to 
hepatotoxicity although little is known currently for the exact 
mechanism on link with the APAP-induced hepatotoxicity.
We also observed that Gabra3 expression level was found 
to be correlated well with the APAP-induced hepatotoxicity 
as shown by significant Spearman correlation coefficient of 
-0.4209 (p<0.05) and -0.4012 (p<0.05) for AST and ALT in-
crease, respectively. Gabra3 has been originally found in the 
CNS but its expression in the liver tissue has been reported 
(Moe et al., 2008; Oh et al., 2009). Moreover, Biju et al. (2001) 
have showed that hepatic GABA-A receptor can give inhibi-
tory signal for hepatic cell proliferation. Bozogluer et al. (2012) 
also showed that flumazenil, a GABA-A receptor antagonist, 
attenuated the APAP-induced hepatotoxicity. Conversely, the 
expression of Gabra3 was down-regulated following the expo-
sure to a hepatotoxicant, 4,4’-methylenedianiline in mice (Oh 
et al., 2009). Despite many contradicting results on the role 
of GABA-A receptor in the liver, we could speculate that the 
susceptibility to APAP-induced hepatotoxicity in the animals 
with innately lower expression of Gabra3 can be attributable 
to the altered signaling for hepatocyte proliferation which is 
important for the recuperation processes.
Previously, we demonstrated that high expression level of 
Pkia in pre-dose blood may be related to the susceptibility to 
APAP-induced hepatotoxicity (Yun et al., 2014). In our micro-
array analysis, however, the difference of Pkia expression 
between susceptible and resistant was only marginal (1.12 
fold higher in susceptible with p-value of 0.055, t-test, data not 
shown) which may be considered confirmatory but unappar-
ent. This discrepancy may be from different species employed 
for the studies (SD rats for blood genes, ICR mice for liver 
genes). Here, we employed ICR mice since this species mani-
fests clear blood chemistry profiles for APAP-induced hepato-
toxicity in contrast to the rat which needs histology to monitor 
APAP-induced hepatotoxicity additional to blood chemistry. 
These results suggest that other experimental animal species 
or strains may produce different genetic markers owing to dis-
tinct physiology and translational clinical research in human is 
ultimately necessary to draw the solid answers.
In conclusion, we demonstrated that the two gene biomark-
ers in the liver pre-biopsied prior to administration were re-
lated to the inter-individual variation in the severity of APAP-
induced hepatotoxicity although other important factors like 
different gastrointestinal absorption of APAP (Sanaka et al., 
1998) or alteration of metabolic capacity like CYP2E1 (Lee et 
al., 1996) could not be examined due to the limitation of study 
design and animal species employed. However, the pre-dose 
expressions of Lpl and Gabra3 in the liver were all correlated 
well with the post-dose changes of ALT, AST, and total biliru-
bin. Accordingly, the data presented in this study suggest a 
novel role of Lpl and Gabra3 in the liver in the manifestation of 
APAP-induced hepatotoxicity. In addition, we could speculate 
that these genes can be employed to screen out individuals 
susceptible to APAP-induced hepatotoxicity although further 
studies should be conducted.
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